LENZ Therapeutics (LENZ) Cash from Operations Growth (3y) (2023 - 2026)

LENZ Therapeutics (LENZ) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,045.06 Bn 1,045.06 Bn - -
4 BeOne Medicines 470.64 Bn 465.84 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 122.91 Bn 115.67 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn -7.60%
7 Belite Bio 62.77 Bn 62.77 Bn - -
8 Argenx Se 56.21 Bn 51.02 Bn 1.41 Bn -
9 Revolution Medicines 37.60 Bn 37.60 Bn - -
10 LENZ Therapeutics 178.71 Mn -79.67 Mn 825,000.00 -37.93%

Historic Data

Download Data
DateValue
Mar 31, 2026 -37.93%
Dec 31, 2025 -13.77%
Sep 30, 2025 27.15%
Jun 30, 2025 19.54%
Mar 31, 2025 8.92%
Dec 31, 2024 16.50%
Sep 30, 2024 11.79%
Jun 30, 2024 -4.64%
Mar 31, 2024 -43.74%
Dec 31, 2023 -58.45%
Sep 30, 2023 -73.80%